SCHEMBL5981676

SCHEMBL5981676

CC(C)CCN(c1cccc(CC(C)CNC(=O)[C@@H](CC(N)=O)NC(=O)c2ccc3ccccc3n2)c1O)S(=O)(=O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 2/20 0.41
CYP3A4 P08684 3/20 0.37
LMNA P02545 2/20 0.37
USP2 O75604 1/20 0.37
CYP2D6 P10635 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
HIF1A Q16665 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ABCC3 O15438 1/20 0.36
ABCC4 O15439 1/20 0.36
CACNA1F O60840 1/20 0.36
ABCB11 O95342 1/20 0.36
ABCB1 P08183 1/20 0.36
HTR1A P08908 1/20 0.36
DRD2 P14416 1/20 0.36
TACR2 P21452 1/20 0.36
TBXAS1 P24557 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7449299 0.82 CA1 (0.43) MMP2CTSKCTSLCTSBCTSS
SCHEMBL3862542 0.78 MMP8 (0.42) ALDH1A1MMP2
SCHEMBL5981554 0.78 MCL1 (0.39) LMNATP53GAA
SCHEMBL7455250 0.76 ADAM17 (0.37) LMNAALDH1A1TP53MMP2MMP13
SCHEMBL7458024 0.75 MMP3 (0.43) CTSKCTSLCTSBCTSS
SCHEMBL2575749 0.73 CYP3A4 (0.54) CTSDCYP3A4LMNAUSP2CYP2D6
SCHEMBL13840781 0.73 CYP3A4 (0.54) CTSDCYP3A4LMNAUSP2CYP2D6
SCHEMBL5996194 0.72 CYP2C8 (0.40) LMNAGAA
SCHEMBL8622935 0.71 CTSD (0.45) CTSDCYP3A4LMNAUSP2CYP2D6
SCHEMBL4848012 0.70 ESR1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020052399-A1 Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors VAZQUEZ MICHAEL L (US) 2002-05-02 US claimed
US-7141609-B2 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 2006-11-28 US disclosed
US-20050267171-A1 Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE & CO. (US) 2005-12-01 US disclosed
US-20030191319-A1 Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE & CO. 2003-10-09 US disclosed
US-6417387-B1 IN PARTICULAR AS INHIBITORS OF HIV PROTEASE. G.D. SEARLE & CO. 2002-07-09 US disclosed
US-6046190-A FOR INHIBITING RETROVIRAL PROTEASES SUCH AS HUMAN IMMUNODEFICIENCY VIRUS G.D. SEARLE & CO. (US) 2000-04-04 US disclosed
WO-1995006030-A1 HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1995-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052399-A1 Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors DNPEP, ASPH, PREP CTSD 173/4885CYP3A4 2672/4885LMNA 2536/4885
US-20050267171-A1 Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors DNPEP, ASPH, PREP CTSD 136/4885CYP3A4 2857/4885LMNA 2140/4885
US-20030191319-A1 Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors DNPEP, ASPH, PREP CTSD 173/4885CYP3A4 2672/4885LMNA 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.